Quarterly ResultMay 5, 2026, 07:33 AM
Compass Therapeutics Reports Positive Tovecimig Phase 2/3 Data; Q1 Results
AI Summary
Compass Therapeutics reported positive Phase 2/3 data for tovecimig in biliary tract cancer, demonstrating statistically significant improvement in progression-free survival and overall response rate, with plans for a BLA submission later this year. The company also provided updates on its pipeline, including an upcoming ASCO presentation for CTX-8371 and the initiation of a Phase 1 study for CTX-10726. For Q1 2026, Compass reported a net loss of $18.3 million and held $195 million in cash and marketable securities, providing a cash runway into 2028.
Key Highlights
- Tovecimig Phase 2/3 study showed 4.7 months PFS vs 2.6 months for paclitaxel alone (HR=0.44, p<0.0001).
- Overall Response Rate for tovecimig combination was 17.1% vs 5.3% for paclitaxel alone (p=0.031).
- CTX-8371 Phase 1 dose-escalation study selected for ASCO 2026 poster presentation.
- CTX-10726 Phase 1 study initiated with initial data expected in Q4 2026.
- Cash and marketable securities were $195 million at Q1 2026, funding operations into 2028.
- Net loss for Q1 2026 was $18.3 million, or $0.10 per common share.
- R&D expenses increased 3% to $13.4 million in Q1 2026.
- G&A expenses increased 41% to $6.9 million in Q1 2026, driven by pre-commercialization and stock compensation.